Generic drug of the therapeutic class: Oncology and Hematology
active ingredients: Dolasétron mesilate
laboratory: Sanofi-Aventis France
Box of 1
Prevention of acute nausea and vomiting induced by moderately emetic cytotoxic chemotherapy in adults.
Dosage ANZEMET 200 mg Film-coated tablet Box of 1
Reserved for adults over 15 years of age: 200 mg daily administered within one hour before the start of chemotherapy.
It is useless to continue the treatment more than 24 hours.
No dosage adjustment is recommended in the elderly or renal or hepatic impairment.
Hypersensitivity to dolasetron or any of the components of the drug.
Due to the presence of lactose, this drug is contraindicated in cases of congenital galactosemia, glucose-galactose malabsorption syndrome or lactase deficiency.
NOT RECOMMENDED :
Prescription is not recommended for patients with atrioventricular block, branch block, long QT interval, or history of arrhythmia.
Breast-feeding: If breastfeeding or breast-feeding is desired, use of this product is not recommended in the absence of data.
Side effects Anzemet
- have been reported in clinical studies:
. headache, dizziness,
. transient elevation of transaminases,
. lengthening of PR, QRS, QT intervals
. in clinical trials, hypotension was observed in 1.9% of dolasetron patients; the incidence of this event was similar in placebo patients.
In very rare cases, severe hypotension with bradycardia and possible loss of consciousness may occur during or immediately following an intravenous bolus injection of dolasetron mesilate.
- As with other 5-HT3 receptor antagonists, hypersensitivity reactions such as rash, pruritus, urticaria, bronchospasm, and very rare cases of angioedema and anaphylaxis reactions have been reported.